Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose escalation study that will determine the maximum
tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single
agent for the treatment of subjects with AML that is refractory to or relapsed after
induction therapy